 - Anti-convulsants: Patients who are currently receiving CYP3A4PgP enzyme inducing anticonvulsants eg. phenytoin, phenobarbitol, or carbamazepine are not eligible. Stabilizing on a non-hepatic inducing metabolizing anti-convulsant ie: gabapentin or levetiracetam prior to study entry is acceptable. At least 3 half-lives must have elapsed after the last dose of enzyme inducing anti-convulsants. 